Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Change in Receivables (2021 - 2026)

Corvus Pharmaceuticals' Change in Receivables history spans 6 years, with the latest figure at $6000.0 for Q1 2026.

  • Quarterly Change in Receivables rose 50.0% to $6000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$36000.0 through Mar 2026, down 161.02% year-over-year, with the annual reading at -$38000.0 for FY2025, 177.55% down from the prior year.
  • Change in Receivables came in at $6000.0 for Q1 2026, up from $5000.0 in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $130000.0 in Q3 2022 to a low of -$429000.0 in Q2 2023.
  • The 5-year median for Change in Receivables is $5500.0 (2024), against an average of -$33785.7.
  • Year-over-year, Change in Receivables surged 218.18% in 2024 and then tumbled 254.29% in 2025.
  • Corvus Pharmaceuticals' Change in Receivables stood at $85000.0 in 2022, then crashed by 82.35% to $15000.0 in 2023, then plummeted by 66.67% to $5000.0 in 2024, then changed by 0.0% to $5000.0 in 2025, then rose by 20.0% to $6000.0 in 2026.
  • Per Business Quant, the three most recent readings for CRVS's Change in Receivables are $6000.0 (Q1 2026), $5000.0 (Q4 2025), and -$54000.0 (Q3 2025).